About: Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How? Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	The cost and effectiveness patterns in the treatment of secondary hyperparathyroidism (SHPT) in dialysis patients in the Czech Republic are unknown. 52 dialysis patients from 17 centers were followed up in a multicenter prospective study of laboratory and clinical responses to 12-month cinacalcet treatment. Treatment patterns and cost (including phosphate binders, vitamin D, and cinacalcet) were evaluated. The mean s-Ca, s-P, CaP, and iPTH dropped significantly. The mean cinacalcet dose reached 44.1 23.0 mg/day after 12 months. Itching intensity decreased significantly. The direct cost of daily SHPT treatment rose significantly from EUR 8.77 9.59 to 20.62 9.22. Cinacalcet decreased elevated s-Ca, s-P, CaP, and iPTH, alleviated itching, and significantly raised the SHPT treatment cost. A minority of patients reached K/DOQI targets, especially due to poor phosphate control caused by insufficient phosphate binder treatment, cinacalcet underdosing, and advanced SHPT. The cost and effectiveness patterns in the treatment of secondary hyperparathyroidism (SHPT) in dialysis patients in the Czech Republic are unknown. 52 dialysis patients from 17 centers were followed up in a multicenter prospective study of laboratory and clinical responses to 12-month cinacalcet treatment. Treatment patterns and cost (including phosphate binders, vitamin D, and cinacalcet) were evaluated. The mean s-Ca, s-P, CaP, and iPTH dropped significantly. The mean cinacalcet dose reached 44.1 23.0 mg/day after 12 months. Itching intensity decreased significantly. The direct cost of daily SHPT treatment rose significantly from EUR 8.77 9.59 to 20.62 9.22. Cinacalcet decreased elevated s-Ca, s-P, CaP, and iPTH, alleviated itching, and significantly raised the SHPT treatment cost. A minority of patients reached K/DOQI targets, especially due to poor phosphate control caused by insufficient phosphate binder treatment, cinacalcet underdosing, and advanced SHPT. (en)
Title	Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How? Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How? (en)
skos:prefLabel	Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How? Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How? (en)
skos:notation	RIV/68081740:_____/10:00350402!RIV11-AV0-68081740
http://linked.open...avai/riv/aktivita	Z
http://linked.open...avai/riv/aktivity	Z(AV0Z70250504)
http://linked.open...iv/cisloPeriodika	5
http://linked.open...vai/riv/dodaniDat	2011
http://linked.open...aciTvurceVysledku	Urbánek, Tomáš
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Psychologický ústav AV ČR, v. v. i.
http://linked.open...dnocenehoVysledku	250794
http://linked.open...ai/riv/idVysledku	RIV/68081740:_____/10:00350402
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Cinacalcet; Itching; Phosphate binders (en)
http://linked.open.../riv/klicoveSlovo	Cinacalcet Itching Phosphate binders
http://linked.open...odStatuVydavatele	CH - Švýcarská konfederace
http://linked.open...ontrolniKodProRIV	[D830BCDF7681]
http://linked.open...i/riv/nazevZdroje	Kidney & Blood Pressure Research
http://linked.open...in/vavai/riv/obor	FE
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	2 (xsd:int)
http://linked.open...UplatneniVysledku	2010
http://linked.open...v/svazekPeriodika	33
http://linked.open...iv/tvurceVysledku	Urbánek, Tomáš Smržová, J.
http://linked.open...ain/vavai/riv/wos	000284644200001
http://linked.open...n/vavai/riv/zamer	Člověk v kontextech celoživotního vývoje
issn	1420-4096
number of pages	10 (xsd:int)
is http://linked.open...avai/riv/vysledek of	Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How? Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How? Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How?

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software